Abstract
We report the case of a type 2 diabetes subject who developed severe leucopenia associated with treatment with the dipeptidil-peptidase 4 enzyme inhibitor Sitagliptin and highlights DPP4 inhibitors as a possible cause of unexplained hematolgical abnormalities in patients receiving DPP4-inhibitor treatment.
Lingua originale | English |
---|---|
pagine (da-a) | 30-32 |
Numero di pagine | 3 |
Rivista | Diabetes Research and Clinical Practice |
Volume | 91 |
Stato di pubblicazione | Pubblicato - 2011 |
Keywords
- Leucopenia
- Sitagliptin